TYMS and frontotemporal dementia: Sorafenib-mediated reductions in TS expression contributed directly to proapoptotic activity [19]; therefore, regorafenib-mediated reductions in TS expression might be the main factor underlying the apoptosis observed after sequential exposure to FTD followed by regorafenib (Figure 3).